Pamela Esposito

Sits on 1 board. Last updated September 28, 2026

Time on boards

Boards served
1
Current seats
1
Board service
3 years
Director since
2023

3 years of board service in total across 1 board, counting each seat separately. Longest: Kymera Therapeutics Inc., 3 years.

3 years · Since 2023

Shareholder support

Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Date Company Transaction Shares Price Value
May 19, 2026 Kymera Therapeutics Inc. Option exercise +1,000 $31.20 $31,200
Mar 20, 2026 Kymera Therapeutics Inc. Option exercise +2,500 $49.10 $122,750
Mar 20, 2026 Kymera Therapeutics Inc. Open-market sale −700 $77.71 $54,397
Mar 20, 2026 Kymera Therapeutics Inc. Open-market sale −600 $79.24 $47,544
Mar 20, 2026 Kymera Therapeutics Inc. Open-market sale −1,200 $79.94 $95,928
Feb 20, 2026 Kymera Therapeutics Inc. Option exercise +2,500 $49.10 $122,750
Feb 20, 2026 Kymera Therapeutics Inc. Open-market sale −1,900 $87.06 $165,414
Feb 20, 2026 Kymera Therapeutics Inc. Open-market sale −600 $88.10 $52,860
Jan 20, 2026 Kymera Therapeutics Inc. Option exercise +3,000 $31.20 $93,600
Jan 20, 2026 Kymera Therapeutics Inc. Option exercise +2,500 $49.10 $122,750
Jan 20, 2026 Kymera Therapeutics Inc. Open-market sale −400 $66.68 $26,672
Jan 20, 2026 Kymera Therapeutics Inc. Open-market sale −4,900 $67.99 $333,151
Jan 20, 2026 Kymera Therapeutics Inc. Open-market sale −200 $68.52 $13,704
Dec 17, 2025 Kymera Therapeutics Inc. Option exercise +12,563 $49.10 $616,843
Dec 17, 2025 Kymera Therapeutics Inc. Option exercise +12,000 $27.67 $332,040

Questions about Pamela Esposito

What boards is Pamela Esposito on?

Pamela Esposito sits on the board of Kymera Therapeutics Inc.

How long has Pamela Esposito served on boards?

Our records show at least 3 years of board service across 1 board, the earliest from 2023.

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.